Peter Nordkild
Chief Executive Officer at ASARINA PHARMA AB
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Sten Gunnar Otto Skolling | M | 63 | 13 years | |
| Paul de Potocki | M | 62 | 6 years | |
| Marianne Kock | F | 69 | 6 years | |
| Ove Andersen | M | - |
Oracain ApS
 Oracain ApS Pharmaceuticals: MajorHealth Technology Oracain ApS develops oral pain medications based on known active compounds. It is developing a novel pharmaceutical product for pain associated with oral mucositis and other complex conditions. The company was founded by Ove Andersen in 2011 and is headquartered in Lyngby, Denmark. | 13 years |
| Erin Elizabeth Gainer | M | 50 | 4 years | |
| Jakob Dynnes Hansen | M | 69 | 7 years | |
| Adam Sinding Steensberg | M | 50 |
Dansk Biotek
 Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | - |
| Lone Dybdal Nilsson | F | - |
Dansk Biotek
Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | 3 years |
| Mark DuBois | M | - | - | |
| Magnus Brisander | M | - | - | |
| Dorte Dannemann | F | - |
Dansk Biotek
Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | - |
| Camilla Sylvest | F | 52 | 28 years | |
| Britt Meelby Jensen | F | 51 |
Dansk Biotek
Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | - |
| Hans Schambye | M | 59 |
Dansk Biotek
Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | - |
| Mai-Britt Zocca | M | 56 |
Dansk Biotek
Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | 5 years |
| Alejandra Maria Mørk | M | 63 |
Dansk Biotek
Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | - |
| Søren Møller | M | 56 |
Dansk Biotek
Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | - |
| Henrik Blou | M | 45 |
Dansk Biotek
Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | - |
| Jørgen Godt Olsen | M | - |
Dansk Biotek
Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jakob Riis | M | 58 | 21 years | |
| Knud Carsten Lønfeldt | M | 77 | 6 years | |
| Marianne Weile Nonboe | F | 64 | 4 years | |
| Niels Tækker Foged | M | 63 | 6 years | |
| Karl-Olof Borg | M | 83 |
Pharmexa A/S
 Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | - |
| Mathieu Simon | M | 68 | - | |
| Achim Kaufhold | M | 66 |
Pharmexa A/S
Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | 2 years |
| Valeta A. Gregg | M | 72 | 5 years | |
| Martin Olin | M | 55 | 4 years | |
| Hans Henrik Chrois Christensen | M | 59 |
Pharmexa A/S
Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | - |
| Patrick Loustau | M | 61 | 14 years | |
| Annette Stube | F | 57 | 11 years | |
| Christopher Yallop | M | - | 6 years | |
| André Ulmann | M | - | 2 years | |
| René Djurup | M | - | 4 years | |
| Gry Louise Husby Larsen | F | - | 8 years | |
| Laura von Kobyletzki | M | 53 | 1 years | |
| Miroslav Reljanovic | M | 65 | 3 years | |
| Gitte L. Pedersen | F | 61 | 10 years | |
| Zaiton binti Jamaluddin | F | 65 | 8 years | |
| Vidar Wendel-Hansen | M | 65 | 1 years | |
| Michel Lucien Pettigrew | M | 71 |
Pharmexa A/S
Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | - |
| Roar Bjørk Seeger | M | 60 | - | |
| Alf E. A. Lindberg | M | 85 |
Pharmexa A/S
Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | - |
| Arne Jensen Gillin | M | - |
Pharmexa A/S
Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | - |
| Bruce Carter | M | 80 | 4 years | |
| Ole Steen Andersen | M | 78 |
Pharmexa A/S
Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | - |
| Mark Newman | M | 69 |
Pharmexa A/S
Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | 2 years |
| Thomas Magnussen | M | 71 | 8 years | |
| Christian Gröndahl | M | 60 | 14 years | |
| Jakob Schmidt | M | - |
Pharmexa A/S
Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | - |
| Jørgen Buus Lassen | M | 90 |
Pharmexa A/S
Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | - |
| Jens Jesper Ovesen | M | 67 | 4 years | |
| Finn M. Ulrich | M | - | 8 years | |
| Thomas Feldthus | M | 64 | 3 years | |
| Claude Mikkelsen | M | - |
Pharmexa A/S
Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | 4 years |
| Karen Lykke Sorensen | F | - |
Pharmexa A/S
Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | - |
| Jan Ulf Sigvar J. Johansson | M | 79 | 7 years | |
| Märta Segerdahl | M | 68 | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Denmark | 46 | 79.31% |
| Sweden | 12 | 20.69% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Peter Nordkild
- Personal Network
